PARP1 and cancer: In addition, some studies show that cancers with genetic deficiencies involved in homologous recombination repair other than BRCA mutations, such as deficiencies in ATM, ATR, PALB2, and FANC, are also highly susceptible to PARP inhibitor treatment10,11.